Search

Displaying results 2581 - 2590 of 8196 in total
  1. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

  2. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury.

  3. Target

    Transforming growth factor beta activator LRRC32

    go.drugbank.com/bio_entities/BE0014554
    TargetHumans

    Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19651619, PubMed:19750484, PubMed:22278742). As...

    Synonyms: Leucine-rich repeat-containing protein 32
  4. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins

  5. Drug

    Quinidine barbiturate

    go.drugbank.com/drugs/DB01346
    Approved

    A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)

  6. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237] This drug was first approved in Japan on 25 March 2013.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.

    Synonyms: hypoxanthine D-riboside, 9-β-D-ribofuranosylhypoxanthine
  8. Drug

    Estradiol acetate

    go.drugbank.com/drugs/DB13952
    ApprovedVet approved

    Estradiol acetate is commercially available as Femring, a vaginal ring used for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause. … [DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A1 Substrates
  9. Drug

    3-Methylfentanyl

    go.drugbank.com/drugs/DB01571
    ExperimentalIllicit

    3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000

  10. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one